Singapore, Singapore

Cleofe Calanasan

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Uniquest Pty Limited. Active years: 2014.


 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Cleofe Calanasan: Innovator in Antimicrobial Therapeutics

Introduction

Cleofe Calanasan is a distinguished inventor based in Singapore, known for her contributions to the field of therapeutic compounds. She has made significant strides in developing innovative solutions to combat microbial infections, particularly through her research on lipopeptide compounds.

Latest Patents

Calanasan holds a patent for "Lipopeptide compounds and their use." This invention pertains to therapeutic compounds, specifically certain lipopeptide compounds that comprise a cyclic peptide bearing a lipid side chain. These compounds, collectively referred to as 'LP compounds,' exhibit antimicrobial properties, particularly antibacterial effects. The patent also covers pharmaceutical compositions that include these compounds and their applications in treating diseases mediated by microbes, especially bacterial infections.

Career Highlights

Throughout her career, Cleofe Calanasan has demonstrated a commitment to advancing medical science through her innovative research. Her work has the potential to significantly impact the treatment of bacterial diseases, offering new avenues for therapeutic intervention.

Collaborations

Calanasan has collaborated with notable colleagues, including Rustum S Boyce and Joseph Cherian, to further her research and development efforts in the field of antimicrobial therapeutics.

Conclusion

Cleofe Calanasan's contributions to the field of therapeutic compounds highlight her role as a leading inventor in antimicrobial research. Her innovative work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…